Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN.
Department of Radiology, Mayo Clinic, Rochester, MN.
Hepatology. 2021 May;73(5):1868-1881. doi: 10.1002/hep.31575. Epub 2021 Apr 19.
Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection.
This is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed.
MRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.
在原发性硬化性胆管炎 (PSC) 患者中早期发现肝门部胆管癌 (CCA) 对于确定更多适合根治性治疗的患者非常重要。尽管许多人建议进行 CCA 筛查,但对于早期 CCA 检测中使用超声或磁共振成像 (MRI) 存在不同意见和有限的数据,并且尚不清楚在无症状个体中进行检测是否有益。我们的目的是评估基于超声和 MRI 的 CCA 检测的诊断性能和预后意义。
这是一项多中心回顾性研究,纳入了 266 名 PSC 成人患者(CCA 患者 n=120),他们在 3 个月内同时接受了超声和 MRI 检查。放射科医生在不知道临床信息的情况下重新检查了图像。对于整个队列,MRI 对 CCA 检测的曲线下面积 (AUC) 高于超声:0.87 比 0.70;对于无症状个体,AUC 分别为 0.81 比 0.59;对于列入 CCA 移植协议的个体,AUC 分别为 0.88 比 0.71。CCA 诊断时无症状与改善的 5 年结局相关,包括总生存率(82%比 46%,对数秩 P<0.01)和肝移植后无复发生存率(89%比 65%,对数秩 P=0.04)。在无症状 CCA 患者中,与超声相比,MRI 检测(与超声相比)与死亡率降低相关(风险比,0.10;95%置信区间,0.01-0.96)和移植名单后 CCA 进展减少(风险比,0.10;95%置信区间,0.01-0.90)。这些益处在 CCA 诊断前 PSC 监测和随访超过 1 年的患者中仍然存在。
在 PSC 患者中,MRI 优于超声用于检测早期 CCA。MRI 在症状出现前识别 CCA 与改善结局相关。